November 13, 2026
TB LAT Pipeline Report 2026
Pipeline Report
This pipeline report represents Treatment Action Group’s pioneer effort to track the development of long-acting technologies (LATs) for tuberculosis (TB), an area of increasing interest and activity in the field.
November 11, 2026
TAG and Global TB Community Advisory Board Will Bring Community Voices to Union World Conference on Lung Health in Rio
Statement / Press
With a voice in more than 20 sessions at the 2026 Union World Conference on Lung Health, Treatment Action Group (TAG) and members of the Global Tuberculosis Community Advisory Board (TB CAB) will bring a robust presence to Rio de Janeiro, Brazil.
November 4, 2026
An Activist’s Guide to Diagnostic Tools for Tuberculosis 2026
Publication
This Activist’s Guide is designed to help readers navigate the TB diagnostic pathway and to provide TB advocates and community members with the information they need to advocate for access to the highest standard of TB diagnostic testing.
October 28, 2026
TB Treatment Pipeline Report 2026
Pipeline Report
The pipeline of new TB drugs is busy with candidates advancing more quickly than ever before. But questions important for informing the eventual introduction of the next generation of new treatments to TB programs aren’t yet being addressed by the ongoing or planned studies catalogued in the 2026 TB Treatment…
October 21, 2026
TB Vaccines Pipeline Report 2026
Pipeline Report
From pivotal trial results to manufacturing milestones, 2026 reshaped the TB vaccine landscape. But scientific progress is only one part of the story, the field must also face the formidable task of turning research into action.
September 16, 2026
Infections Post-inequalities: Realizing the End of Tuberculosis Through Equitable Economic Orders
Publication
This article, Infections Post-inequalities: Realizing the End of Tuberculosis Through Equitable Economic Orders, explores TB as a proxy metric for the failure to dismantle colonial structures in global health and to realize the rights to health and science. Fundamentally, the paper calls for reforming the international financial architecture along the…
September 4, 2026
Inhumane ICE Detention Center Practices Create Ideal Conditions for TB
Statement / Press
Contact: adam.ortega@treatmentactiongroup.org New York, September 4, 2026 – Treatment Action Group (TAG) calls for immediate provision of tuberculosis (TB) prevention and care, access to robust healthcare services, and healthy living conditions for all those held in detention by the U.S. Immigration and Customs Enforcement (ICE) and for the unencumbered access…
August 27, 2026
TAG Welcomes Discounted Price for New Near Point of Care (NPOC) TB Tests Available Immediately
Statement / Press
Contact: Teju Dharmapuri Vachaspathi, teju.dv@treatmentactiongroup.org August 20, 2026 — Treatment Action Group (TAG) welcomes the access price for PlusLife MiniDock MTB near point-of-care (NPOC) tuberculosis (TB) tests, now newly available for $2.60 per test. PlusLife MiniDock MTB is the first product in the new NPOC test class recommended by the…
August 19, 2026
Community Materials on Drug-Resistant Tuberculosis
This suite of materials is designed to build community treatment literacy on the side effects of medications used to treat DR-TB and to support community engagement in active drug safety monitoring and management (ADSM) initiatives.
August 6, 2026
Upcoming Drug-Resistant Tuberculosis Webinars: August 19 & August 20, 9:00 AM EST
On Aug. 19 & 20, TAG is hosting a two-part webinar covering WHO guideline updates for pre-extensively drug-resistant TB and approaches to addressing additional bedaquiline-resistance (extensively drug-resistant TB).
July 20, 2026
Letters Advocating for the Adoption of Near-Point-of-Care TB tests
Letter / Comment
TAG and the Global TB CAB have a long history of advocating for the uptake of new health innovations, influencing global and national decision-making, and supporting policy translation. In March 2026, the World Health Organization (WHO) recommended a new class of tests — near point-of-care (NPOC) molecular tests — that…
July 13, 2026
Why So Long? A Call for a More Humane Tuberculosis Treatment and Meaningful Community Engagement
Poetry can be used as a form of public health. In a recently written poem, LAT CAB member Bakyt Myrzaliev speaks about the trials and tribulations of tuberculosis treatment – writing passionately and inquisitively about side effects, the high burden of countless pills, and ultimately calling for investments into newer…
July 9, 2026
Webinar: Implementing the 4-month HPMZ Regimen: Experience, Tools, and Next Steps
Webinar / Presentation
The WHO Global TB Program’s Accelerator Platform for Novel TB Regimens held its 12th meeting to examine the four-month HPMZ (isoniazid, rifapentine, moxifloxacin, pyrazinamide) regimen for tuberculosis treatment, covering country experiences, implementation tools, and next steps for rollout. Despite the World Health Organization’s (WHO) 2022 recommendation, implementation has remained limited,…
July 6, 2026
Community Research Advisors Group (CRAG) Consultant
Treatment Action Group (TAG) is seeking a consultant to coordinate and strengthen the work of the Community Research Advisors Group (CRAG), one of the longest-running community advisory boards in tuberculosis (TB) research.
June 23, 2026
Overcoming Barriers to Adopting the Four-Month Regimen: A Pathfinding Mission to Improve Access to Newer TB Treatments
Publication
A landmark tuberculosis study showed that drug-sensitive TB can be treated in four months instead of six using the WHO-endorsed HPMZ regimen. This factsheet examines barriers to adoption, the role of new fixed-dose combinations, Global Fund GC8 funding opportunities, and advocacy strategies to expand access